(RNA) Avidity Biosciences - Ratings and Ratios
Antibody, Oligonucleotide, Conjugates, RNA, Therapeutics
RNA EPS (Earnings per Share)
RNA Revenue
Description: RNA Avidity Biosciences
Avidity Biosciences, Inc. is a biopharmaceutical company that specializes in developing RNA therapeutics through its proprietary antibody oligonucleotide conjugates (AOCs) platform. This technology combines the specificity of monoclonal antibodies with the precision of RNA therapeutics, allowing for targeted treatment of diseases that were previously untreatable.
The companys pipeline is robust, with three programs in registrational clinical trials, including Delpacibart etedesiran for myotonic dystrophy type 1, Delpacibart braxlosiran for facioscapulohumeral muscular dystrophy, and Delpacibart zotadirsen for Duchenne muscular dystrophy. Additionally, Avidity is developing precision cardiology candidates, such as AOC1086 and AOC1072, targeting rare genetic cardiomyopathies.
From a financial perspective, Avidity Biosciences has a market capitalization of approximately $4.07 billion. The companys return on equity (ROE) is -26.96%, indicating significant investment in research and development. Key performance indicators (KPIs) to watch include the progress of its clinical trials, particularly the Phase 3 trial for Delpacibart etedesiran, and the potential for future partnerships or collaborations. Other relevant KPIs include the companys cash burn rate, R&D expenses as a percentage of revenue, and the overall growth of its pipeline.
Given the current market price of $36.88 and the SMA20, SMA50, and SMA200 values, the stock appears to be in an uptrend. Investors should monitor the stocks ability to sustain its price above these moving averages and watch for potential breakouts or pullbacks. Furthermore, the high ATR value of 4.98% indicates significant price volatility, which may present both opportunities and risks for traders.
RNA Stock Overview
| Market Cap in USD | 6,123m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2013-06-28 |
RNA Stock Ratings
| Growth Rating | 32.2% |
| Fundamental | 25.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -16.4% |
| Analyst Rating | 4.60 of 5 |
RNA Dividends
Currently no dividends paidRNA Growth Ratios
| Growth Correlation 3m | 87.8% |
| Growth Correlation 12m | -18.1% |
| Growth Correlation 5y | 29.8% |
| CAGR 5y | 25.28% |
| CAGR/Max DD 3y | 0.31 |
| CAGR/Mean DD 3y | 0.69 |
| Sharpe Ratio 12m | -0.67 |
| Alpha | 0.11 |
| Beta | 0.354 |
| Volatility | 106.17% |
| Current Volume | 3380.7k |
| Average Volume 20d | 2497.4k |
| Stop Loss | 38.5 (-7.1%) |
| Signal | 0.28 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-455.7m TTM) > 0 and > 6% of Revenue (6% = 643.7k TTM) |
| FCFTA -0.22 (>2.0%) and ΔFCFTA -13.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.4k% (prev 11.7k%; Δ -1345 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.36 (>3.0%) and CFO -490.0m <= Net Income -455.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 9.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (129.6m) change vs 12m ago 21.22% (target <= -2.0% for YES) |
| Gross Margin 78.92% (prev 89.73%; Δ -10.81pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.79% (prev 0.79%; Δ 0.00pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -6.95
| (A) 0.81 = (Total Current Assets 1.25b - Total Current Liabilities 135.1m) / Total Assets 1.37b |
| (B) -0.85 = Retained Earnings (Balance) -1.17b / Total Assets 1.37b |
| (C) -0.38 = EBIT TTM -522.6m / Avg Total Assets 1.36b |
| (D) -6.61 = Book Value of Equity -1.16b / Total Liabilities 176.3m |
| Total Rating: -6.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.59
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -6.18% = -3.09 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.04 = 2.50 |
| 5. Debt/Ebitda -0.09 = -2.50 |
| 6. ROIC - WACC (= -45.63)% = -12.50 |
| 7. RoE -33.45% = -2.50 |
| 8. Rev. Trend 6.68% = 0.50 |
| 9. EPS Trend -36.36% = -1.82 |
What is the price of RNA shares?
Over the past week, the price has changed by -11.11%, over one month by -6.83%, over three months by +39.06% and over the past year by -0.74%.
Is Avidity Biosciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RNA is around 38.62 USD . This means that RNA is currently overvalued and has a potential downside of -6.81%.
Is RNA a buy, sell or hold?
- Strong Buy: 9
- Buy: 6
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RNA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 67 | 61.7% |
| Analysts Target Price | 67 | 61.7% |
| ValueRay Target Price | 42.6 | 2.7% |
Last update: 2025-09-05 04:58
RNA Fundamental Data Overview
CCE Cash And Equivalents = 1.18b USD (Cash And Short Term Investments, last quarter)
P/S = 570.6586
P/B = 5.1368
Beta = 0.947
Revenue TTM = 10.7m USD
EBIT TTM = -522.6m USD
EBITDA TTM = -519.5m USD
Long Term Debt = 41.2m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 3.92m USD (from shortTermDebt, last quarter)
Debt = 45.1m USD (Calculated: Short Term 3.92m + Long Term 41.2m)
Net Debt = -238.8m USD (from netDebt column, last quarter)
Enterprise Value = 4.98b USD (6.12b + Debt 45.1m - CCE 1.18b)
Interest Coverage Ratio = unknown (Ebit TTM -522.6m / Interest Expense TTM 0.0)
FCF Yield = -6.18% (FCF TTM -307.9m / Enterprise Value 4.98b)
FCF Margin = -2870 % (FCF TTM -307.9m / Revenue TTM 10.7m)
Net Margin = -4248 % (Net Income TTM -455.7m / Revenue TTM 10.7m)
Gross Margin = 78.92% ((Revenue TTM 10.7m - Cost of Revenue TTM 2.26m) / Revenue TTM)
Tobins Q-Ratio = -4.28 (set to none) (Enterprise Value 4.98b / Book Value Of Equity -1.16b)
Interest Expense / Debt = 0.87% (Interest Expense 391.0k / Debt 45.1m)
Taxrate = 21.0% (US default)
NOPAT = -522.6m (EBIT -522.6m, no tax applied on loss)
Current Ratio = 9.26 (Total Current Assets 1.25b / Total Current Liabilities 135.1m)
Debt / Equity = 0.04 (Debt 45.1m / last Quarter total Stockholder Equity 1.19b)
Debt / EBITDA = -0.09 (Net Debt -238.8m / EBITDA -519.5m)
Debt / FCF = -0.15 (Debt 45.1m / FCF TTM -307.9m)
Total Stockholder Equity = 1.36b (last 4 quarters mean)
RoA = -33.29% (Net Income -455.7m, Total Assets 1.37b )
RoE = -33.45% (Net Income TTM -455.7m / Total Stockholder Equity 1.36b)
RoCE = -37.23% (Ebit -522.6m / (Equity 1.36b + L.T.Debt 41.2m))
RoIC = -38.36% (NOPAT -522.6m / Invested Capital 1.36b)
WACC = 7.27% (E(6.12b)/V(6.17b) * Re(7.32%)) + (D(45.1m)/V(6.17b) * Rd(0.87%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 8.46%
Discount Rate = 7.32% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -307.9m)
EPS Correlation: -36.36 | EPS CAGR: -47.67% | SUE: -2.79 | # QB: 0
Revenue Correlation: 6.68 | Revenue CAGR: 17.28% | SUE: N/A | # QB: None
Additional Sources for RNA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle